Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
2002 2
2003 5
2004 7
2005 6
2006 8
2007 13
2008 11
2009 10
2010 27
2011 29
2012 18
2013 21
2014 21
2015 15
2016 12
2017 14
2018 15
2019 13
2020 9
2021 11
2022 9
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Results by year

Filters applied: . Clear all
Page 1
Classifying neurocognitive disorders: the DSM-5 approach.
Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, Petersen RC. Sachdev PS, et al. Among authors: paulsen js. Nat Rev Neurol. 2014 Nov;10(11):634-42. doi: 10.1038/nrneurol.2014.181. Epub 2014 Sep 30. Nat Rev Neurol. 2014. PMID: 25266297 Review.
Huntington disease: natural history, biomarkers and prospects for therapeutics.
Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Ross CA, et al. Among authors: paulsen js. Nat Rev Neurol. 2014 Apr;10(4):204-16. doi: 10.1038/nrneurol.2014.24. Epub 2014 Mar 11. Nat Rev Neurol. 2014. PMID: 24614516 Free article. Review.
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu; Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu, et al. Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036. Cell. 2019. PMID: 31398342 Free PMC article.
Vascular contributions to Alzheimer's disease.
Eisenmenger LB, Peret A, Famakin BM, Spahic A, Roberts GS, Bockholt JH, Johnson KM, Paulsen JS. Eisenmenger LB, et al. Among authors: paulsen js. Transl Res. 2023 Apr;254:41-53. doi: 10.1016/j.trsl.2022.12.003. Epub 2022 Dec 15. Transl Res. 2023. PMID: 36529160 Free PMC article. Review.
Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.
Lee JM, Huang Y, Orth M, Gillis T, Siciliano J, Hong E, Mysore JS, Lucente D, Wheeler VC, Seong IS, McLean ZL, Mills JA, McAllister B, Lobanov SV, Massey TH, Ciosi M, Landwehrmeyer GB, Paulsen JS, Dorsey ER, Shoulson I, Sampaio C, Monckton DG, Kwak S, Holmans P, Jones L, MacDonald ME, Long JD, Gusella JF. Lee JM, et al. Among authors: paulsen js. Am J Hum Genet. 2022 May 5;109(5):885-899. doi: 10.1016/j.ajhg.2022.03.004. Epub 2022 Mar 23. Am J Hum Genet. 2022. PMID: 35325614 Free PMC article.
"Pre-symptomatic" Huntington's disease.
Duff K, Beglinger LJ, Paulsen JS. Duff K, et al. Among authors: paulsen js. Handb Clin Neurol. 2008;89:589-98. doi: 10.1016/S0072-9752(07)01255-9. Handb Clin Neurol. 2008. PMID: 18631781 Free PMC article. Review. No abstract available.
Rating scales for cognition in Huntington's disease: Critique and recommendations.
Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development. Mestre TA, et al. Among authors: paulsen js. Mov Disord. 2018 Feb;33(2):187-195. doi: 10.1002/mds.27227. Epub 2017 Dec 26. Mov Disord. 2018. PMID: 29278291 Free PMC article. Review.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1.
Lobanov SV, McAllister B, McDade-Kumar M, Landwehrmeyer GB, Orth M, Rosser AE; REGISTRY Investigators of the European Huntington’s disease network; Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group; Lee JM, MacDonald ME, Gusella JF, Long JD, Ryten M, Williams NM, Holmans P, Massey TH, Jones L. Lobanov SV, et al. Among authors: paulsen js. NPJ Genom Med. 2022 Sep 5;7(1):53. doi: 10.1038/s41525-022-00317-w. NPJ Genom Med. 2022. PMID: 36064847 Free PMC article.
241 results